# First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency

> **NCT07136922** · PHASE1 · RECRUITING · sponsor: **Calla Lily Clinical Care Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Luteal Phase Insuffiency
- Progesterone Delivery

## Interventions

- **COMBINATION_PRODUCT:** 400mg progesterone Callavid - 2hr wear
- **DRUG:** Cyclogest 400 mg
- **COMBINATION_PRODUCT:** 400mg progesterone Callavid - 3hr wear

## Key facts

- **NCT ID:** NCT07136922
- **Lead sponsor:** Calla Lily Clinical Care Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136922, "First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07136922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*